Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

In brief

This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).

Key facts

Study ID
NCT06931405
Run by
Blueprint Medicines Corporation
People needed
105
Starts
2025-05-28
Expected to finish
2026-12-31
Last updated by the study team
2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.